Archives

Omission noninferior to sentinel-lymph-node biopsy for clinically node-negative early-stage invasive breast cancer

Two-year cumulative rate of invasive ipsilateral breast cancer 5.9 and 4.2 percent for guideline-concordant care, active monitoring

Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer

Imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, but not in overall population

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients

Mild procedure also improves physical function through one year of follow-up

Aortic artery calcification correlates with coronary artery calcium and is associated with incident major adverse cardiovascular events

Noninferiority of reduced-dose anticoagulants could not be proven in patients with VTE who need extended anticoagulation

Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone

Improvement seen in KOOS quality of life and visual analog scale scores at six months among patients with refractory knee OA